Brief: Sensei Biotherapeutics Presents Trial-In-Progress Poster For Phase 1/2 Clinical Study Of Sns-101 At Esmo 2023
23/10/2023 13:11
Oct 23 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS TRIAL-IN-PROGRESS POSTER
FOR
PHASE 1/2 CLINICAL STUDY OF SNS-101 AT ESMO 2023
Source text for Eikon: ID:nGNX6bz4Jv
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments